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Chemical compounds studied in this article:
DPPC (PubChem CID: 160339)
DSPC (PubChem CID: 94190)
DSPE-PEG (PubChem CID: 86278269)
Carboxyﬂuorescein (PubChem CID: 123755)
Cholesterol (PubChem CID: 5997)
HEPES (PubChem CID: 23,831)Thermosensitive liposomes (TSL) receive attention due to their rapid externally controlled drug release at tran-
sition temperature in combinationwith hyperthermia. This rapid release feature of TSL occurswhen the liposome
membrane is going through a phase change which results in numerous interfaces, at so-called crystal grain
boundaries. Based on experiencewith TSLs, our group found that thermosensitive liposomes formulated by bina-
ry compositions of DPPC and DSPC at proper ratios are able to exhibit rapid release without incorporation of re-
lease-promoting components. The aim of this study was to understand the mechanism of rapid release from bi-
component DPPC-DSPC based TSL. Based on the investigation of a series of TSLs formulated by different DPPC-
DSPC ratios, and through the analysis of binary-phase diagrams of DPPC-DSPC TSLs, we conclude that inhomoge-
neous crystal grains are formed in bi-component TSL membranes rather than mono-component, thereby facili-
tating content release. The resulting inhomogeneous membrane pattern is affected by DPPC/DSPC ratio, i.e. this
determines the number of interfaces between solid and liquid phases at transition temperature, which can be di-
minished by addition of cholesterol. At appropriate DPPC/DSPC ratio, substantive solid/liquid interfaces can be
generated not only betweenmembrane domains but also between crystal grains in each domain of the liposome
membranes, therefore improving content release from the TSL at transition temperatures.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Release kinetics1. Introduction
Nanoparticle-mediated chemotherapy offers several advantages in
tumor treatment, including reduced side-effects, prolonged circulation
time and possibly improved intratumoral drug accumulation due to
the enhanced permeability and retention (EPR) effect [1]. Especially
lipid-based particles, liposomes, are successfully developed of which
Doxil®/Caelyx® is one of most well-known and widely used. However,
application of nanoparticles also introduces drawbacks, such as failure
to adequately penetrate tumors [2]. The EPR effect is inﬂuenced byrgical Oncology, Section Surgical
75, 3000CA Rotterdam, PO Box
perimental Surgical Oncology,
us MC, Room Ee 0104a, PO Box
agen@erasmusmc.nl
. This is an open access article undertumor microenvironment, tumor type and proﬁle of nanoparticle,
which all may hinder an optimal therapeutic effect of most convention-
al, passively-delivered liposomal formulations [3,4]. Important, and the
key explanation for failure of Doxil® to surpass doxorubicin, is the slow
drug release from the liposome, which limits therapeutic efﬁcacy in
spite of strikingly increased circulation time [5]. Hence, to obtain high
local levels of free and bioavailable drug actively triggered release of en-
capsulated drug at the diseased site is a pursued possibility. One ap-
proach for local delivery is to use thermosensitive liposomes (TSL)
and local hyperthermia (HT), in which the drug is rapid intravascularly
released in the heated area, subsequently followed by massive uptake
by tumor cells due to high concentration gradients.
The concept of thermosensitive liposomes was ﬁrst introduced by
Yatvin et al. [6], reporting a TSL formed by 1,2-dipalmitoyl-sn-glycero-
3-phosphocholine (DPPC) alone or with 1,2-distearoyl-sn-glycero-3-
phosphocholine (DSPC), which generates content release at a phase
transition temperature around 42 °C. Nevertheless, these TSL relatively
slowly release their content limiting further application [7]. To enhance
release from TSL, Needham et al. improved TSL composition bythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Characterization parameters of DPPC-DSPC based CF TSLs. Mean ± SD, N ≥ 3.
TSL composition (mole)
Particle size (nm)
(Z-average)a Polydispersity index
DPPC/DSPE-PEG 100/5
(TSL 100)
117 ± 5 0.07 ± 0.01
DPPC/DSPC/DSPE-PEG 80/20/5
(TSL 80)
119 ± 3 0.05 ± 0.03
DPPC/DSPC/DSPE-PEG 60/40/5
(TSL 60)
113 ± 2 0.07 ± 0.02
DPPC/DSPC/DSPE-PEG 40/60/5
(TSL 40)
120 ± 4 0.04 ± 0.01
DPPC/DSPC/DSPE-PEG 20/80/5
(TSL 20)
115 ± 3 0.05 ± 0.02
DSPC/DSPE-PEG 100/5
(TSL 0)
119 ± 6 0.06 ± 0.02
a The Z-average of particle was reported by Zetasizer, which was measured based on
Comulant model.
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phosphoethanolamine-N-methoxy(PEG)-2000 (DSPE-PEG2000) in
DPPC-based formulations. These LPC-containing TSLs show over 80% re-
lease in a matter of seconds at around 41 °C, achieving a rapid release
proﬁle necessary for intravascular delivery [8,9]. Currently, several dif-
ferent thermosensitive liposomal formulations have been reported [10].
The principle of TSL release is generally thought to result from phase
separation at Tm causing interfaces or gaps in the bilayer enabling con-
tent release [10]. Ickenstein et al. proposed that lipids solidify into gel-
phase domains in themembrane during cooling, and boundaries appear
at adjacent domains due to spherical bending force [11]. Because of a
high degree of disordered lipid-arrangement in domain boundaries,
these regions possess lower melting points. This causes prior phase
transition at domain boundaries, thus generating interfaces between
gel/liquid-crystalline phases, which are in turn responsible for release
of content [11,12]. Surfactant lysolipids tend to migrate to phase inter-
faces and form micelle-structures at phase transition, thus inducing
nano-pores inmembranes,which can be stabilized by PEG-linked lipids.
Together they increase and enlarge the interfaces inﬂicting more rapid
release [9,13]. Based on the same principle, Tagami et al. added Brij sur-
factants into DPPC-based TSL, which exerts comparable fast release in
response to hyperthermia [14].
Most thermosensitive liposomes are formulated on the initially pro-
posedmatrix composed of DPPC andDSPCphospholipids [15–18]. Espe-
cially, in our group we have been working on DPPC-DSPC based
thermosensitive liposomes for years and developed several PEG-DSPE-
modiﬁed DPPC-DSPC based TSLs loaded with different drugs, showing
desired temperature response [19–22]. In the follow-up study, we ob-
served that TSLs formulated at proper DPPC/DSPC ratios exhibit rapid
release at transition temperatures. However, this fast release is likely
not explained by the defect mechanism of Ickenstein [11], and does
not result from the nano-pore effect seen with lysolipid-based TSL as
proposed by Needham et al. [9]. We speculate that apart from bound-
aries between individual domains as defective regions in membranes,
other release regions and factors exist that inﬂuence content release
from DPPC-DSPC based TSLs at transition temperatures. Therefore, in
this study we designed DPPC-DSPC based TSLs, investigated rapid re-
lease at certain DPPC/DSPC ratios during phase transition, and elucidat-
ed the principle to achieve an optimal heat-triggered release DPPC-
DSPC based liposome system.
2. Materials and methods
2.1. Chemicals and agents
1,2-Dipalmitoyl-sn-glycero-3-phosphcholine (DPPC), 1,2-
distearoyl-sn-glycero-3-phosphocholine (DSPC) and 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-PEG2000 (DSPE-PEG) were provid-
ed by Lipoid (Ludwigshafen, Germany). Puriﬁed carboxyﬂuorescein
(CF) was kindly provided by Dr. Lars Lindner and colleagues. PD-10 col-
umns were obtained from GE Healthcare (UK). Cholesterol and other
chemicals were purchased from Sigma Aldrich unless otherwise
speciﬁed.
2.2. Preparation of liposomes
TSLs were composed of DPPC/DSPC/DSPE-PEG in a molar ratio of x /
(100− x) / 5 (x= 100, 80, 60, 40, 20, 0) by using the thin lipid ﬁlm hy-
dration method, followed by heated extrusion [19]. Brieﬂy, 100 μmol of
lipids was dissolved in methanol/chloroform (1/9 v/v) mixed solvent
which was then evaporated at 40 °C, followed by nitrogen ﬂush for
30min to remove residual solvent. The resulting dried lipid ﬁlmwas hy-
drated with CF (100 mM, pH 7.4) solutions at 60 °C. Small unilamellar
vesicles were obtained by extrusion through Nuclepore® (Whatman
Inc., USA) ﬁlters with pore size of 100 nm on a Thermobarrel extruder
at 65 °C (Northern Lipids, Canada). Unencapsulated CF was removedwith a PD-10 column. Diameter (Z-average) and polydispersity index
(PDI) weremeasured by using Zetasizer Nano-ZS (Malvern Instruments
Ltd., UK).
2.3. Differential scanning calorimetry
Determination of TSL phase transition temperatures was done
through differential scanning calorimetry (DSC) (NETZSCH Scientiﬁc In-
struments Ltd. DSC200F). Six DPPC-DSPC based formulations were pre-
pared as mentioned in Section 2.1 with or without CF loading. 30 mg of
liposome with/without encapsulated CF in fetal calf serum (FCS) or in
HEPES solution (pH 7.4), and the appropriate reference solution
(HEPES solution), were added to the sealed aluminum container. The
phase transition temperature range was measured over a temperature
range of 30 to 70 °C at an interval of 5 °C/min increase. High purity nitro-
gen was used as carrier gas at rate of 10 ml/min.
2.4. CF-loaded TSL time- and temperature-dependent release
20 μl of 1 mM [lipid] CF-TSL suspension was added to 2ml 100% FCS
in a quartz cuvette at a series of determined temperature for 10 min.
Real-time release of CF was detected with a water bath combined
spectroﬂuorimetry (Ex. 493 nm/Em. 517 nm, Ex. slit 5 nm/Em. slit
5 nm) (Hitachi F-4500 Fluorescence Spectrophotometer, Japan). The av-
erage ﬂuorescence intensity of the initial 5 swas recorded as I0 of CF-TSL
release, while ﬂuorescence was measured as It at 10 min. After 10 min,
detergent (10% Triton X-100)was used to disrupt all liposomes to mea-
sure maximal CF ﬂuorescence, which was recorded as Imax. Release
(%) = (It− I0) / (Imax− I0) × 100.
2.5. Thermokinetic release of CF-loaded TSL
Time-dependent CF release curves obtained from Section 2.4, were
ﬁtted using three most common kinetic models (which are zero order,
ﬁrst order andHiguchi equations, respectively, see below), to determine
the best-ﬁtting proﬁle of release kinetics and corresponding release rate
[23].
Zero order : Mt: ¼M0 þ k0 t
First order : In 1−Mtð Þ ¼M0−k1 t
Higuchi : Mt: ¼M0 þ kht1=2
whereMt is the amount of content released at time t. M0 is the initial
amount of release at time = 0. k0, k1 and kh represent the release rate
constant of zero-order, ﬁrst-order and Higuchi, respectively. Here, Mt
Fig. 1.DSC scans of empty liposome inHEPES (A), CF-loaded liposomes in HEPES (B) or in FCS (C). TSL100–0 represent liposomes formulated at (100/5:DPPC/PEG), (80/20/5:DPPC/DSPC/
PEG), (60/40/5:DPPC/DSPC/PEG), (40/60/5:DPPC/DSPC/PEG), (20/80/5:DPPC/DSPC/PEG) and (100/5:DSPC/PEG), respectively.
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based on CF ﬂuorescence intensity.
2.6. Activation energy of CF release
Activation energy (Ea) of CF release from TSLs composed of different
DPPC andDSPC ratios can be calculated by usingArrhenius indeﬁnite in-
tegral equation:
In k ¼− Ea=Rð Þ  1=Tð Þ þ B
where k is the CF release rate constant which can be obtained based
on methods mentioned in Section 2.5, B is a constant, R is the universal
gas constant, andT is expressed as thermodynamic temperature inKelvin.
2.7. Statistical analysis
Data were analyzed using Mann-Whitney U test or Kruskal-Wallis
test followed by Dunn test when appropriate. p-Values below 0.05
were considered signiﬁcant.
3. Results
3.1. Differential scanning calorimetry
DPPC-DSPC based liposome formulations with or without encapsu-
lated CF were prepared with diameters between 110 and 120 nm and
PDI below 0.1 (Table 1). Liposomes were measured in FCS and HEPESTable 2
DPPC-DSPC liposome phase transition temperature.
Lipid
composition
Internal
solution
External
solution
Phase
transition
temperature
Initial
temperature
of phase
transition
Terminal
temperature of
phase
transition
100% DPPC
(TSL 100)
HEPES HEPES 41.7 38.7 45.4
CF HEPES 41.0 40.4 43.2
FCS 41.1 40.4 43.4
80% DPPC
(TSL 80)
HEPES HEPES 43.9 41.1 47.0
CF HEPES 43.7 42.5 45.9
FCS 43.6 42.4 45.5
60% DPPC
(TSL 60)
HEPES HEPES 46.8 43.3 49.7
CF HEPES 46.4 44.5 48.6
FCS 46.4 44.5 48.7
40%DPPC
(TSL 40)
HEPES HEPES 49.4 46.5 52.3
CF HEPES 49.5 47.1 51.4
FCS 49.5 47.2 51.5
20% DPPC
(TSL 20)
HEPES HEPES 52.1 50.0 54.3
CF HEPES 52.0 50.2 54.4
FCS 51.9 50.3 53.9
0% DPPC
(TSL 0)
HEPES HEPES 54.6 52.8 57.1
CF HEPES 54.2 53.6 55.9
FCS 54.3 53.6 56.3buffer solution by DSC, respectively. As seen in Fig. 1, Tm increased
with increasing DSPC content in the liposomal composition. Only one
phase transition peak was observed with each formulation and the Tm
was between those for pure DPPC and pure DSPC liposomes. These
data suggest that a molecular dispersion system (solid solution) was
achieved in DPPC-DSPC mixed lipid membranes. By comparison, when
CF was encapsulated, liposomal Tm did not show signiﬁcant changes
in HEPES or FCS solution (Table 2).
3.2. Pseudo-binary phase diagram of DPPC-DSPC liposomes
Based on initial and terminal temperatures of phase transition mea-
sured by DSC in Table 2, a pseudo-binary phase diagram of DPPC-DSPC
liposome is plotted (Fig. 2). Lines in green are the liquidus and solidus
curves of CF-TSL measured in FCS, and lines in red are for samples mea-
sured inHEPES. Almost overlapping curveswere observed in bothmedia.
3.3. Time-dependent release of CF from DPPC-DSPC formulations in FCS
DPPC-DSPC based liposome formulationswith encapsulated CFwere
tested for triggered release in FCS at different temperatures for 600 s, re-
spectively. Each CF release curve (Fig. 3) was ﬁtted by the three release
kinetic equations described in Section 2.5 separately to obtain the best
release equation match for each formulation based on the determina-
tion coefﬁcient R2 (Table 3). A better coefﬁcient of determination was
obtained with the Higuchi release model when 40% or more DPPC was
present in the liposomal composition. While with DPPC content equal
to or lower than 20%, First order kinetics ismore appropriate to describeFig. 2. Pseudo-binary phase diagram of CF TSL plotted from the initiation and completion
temperatures deducted from DCS measurements in HEPES buffer (red line) and FCS
(green line). Samples were formulated as DPPC-DSPC liposomes with CF loading for
measurement. (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of this article.)
Fig. 3. CF time/temperature-dependent release in FCS from TSL100, TSL80, TSL60, TSL40, TSL20 and TSL0. 100–0 indicates the percentage of DPPC. Mean of at least three independent
measurements is depicted.
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models are minor.
3.4. Temperature-dependent release of CF from DPPC-DSPC formulations in
FCS
Temperature-dependent release of the six DPPC-DSPC based lipo-
some formulations was compared at appropriate temperature rangesTable 3
Kinetic proﬁle of CF release from DPPC-DSPC based liposomal formulations.
Determination coefﬁcient R2
TSL100 TSL80 TSL60 TSL40 TSL20 TSL0
Zero order 0.92797 0.91903 0.85759 0.88797 0.92630 0.94131
First order 0.91137 0.92038 0.89323 0.91025 0.93410 0.94322
Higuchi 0.93806 0.95473 0.91194 0.95473 0.92467 0.89401
Determination coefﬁcientwasdetermined by curveﬁttingof at least 3 independent exper-
iments per formulation. Mean is depicted.
Fig. 4. A: temperature-dependent CF release from DPPC-DSPC based liposomes in FCS. Mean±
CF TSL plotted on the basis of CF release, inwhich release-starting temperaturewas recorded as
followed by Dunn test, p value b 0.05.(Fig. 4A). It was observed that with increasing temperature, regardless
of DPPC-DSPC composition, CF release from TSLs gradually increased
until reaching the maximum release temperature (Tm), and was then
followed by a rapid decrease as the temperature increased further. Ad-
ditionally, the maximum CF release at Tm from TSLs showed a signiﬁ-
cant improvement with lower DPPC content; the highest release
reached 73 ± 4% from TSL20, while only 42 ± 6% release was observed
fromTSL80 at their Tm, respectively. Liposomes composed of pure DSPC
or DPPC showed however a reduced release of CF compared with other
binary-component liposomes during phase transition (Fig. 4A). Based
on calculations with the proper ﬁtting release equations, CF release
rate constants of each formulation were computed at Tm, respectively
(Table 4). As seen, kTm shows similar trend with the change of the
amount of DSPC in TSL.
A CF-release pseudo-binary phase diagramof DPPC-DSPC based TSLs
was plotted based on measured temperature release ranges shown in
Fig. 4B, which demonstrates similar proﬁles with DSC based phase
diagram.SEM are shown of at least 3 independent experiments. B: Pseudo-binary phase diagram of
onset of Tm and release cease-decrease temperature as the end of Tm. *Kruskal-Wallis test
Table 4
CF release rate constants at Tm of DPPC-DSPC based liposomal formulations. Mean ± SD.
TSL100 TSL80 TSL60 TSL40 TSL20 TSL0
kTm (10−4)a 130 ± 1 s−1/2 290 ± 104 s−1/2 580 ± 139 s−1/2 640 ± 193 s−1/2 270 ± 48 s−1 140 ± 75 s−1
a Based on determination coefﬁcient shown in Table 3, the release rate constants k were calculated by the most ﬁt release equation at transition temperatures of each formulation
(Higuchi: TSL100–40; First order: TSL20–0) and presented as 10−4 s−1/2 or 10−4 s−1. The ﬁrst 20 s of measurement at Tm were used for calculation of k [16].
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Based on CF release data in Fig. 4 and the Arrhenius equation, the ac-
tivation energy of CF release from these different liposomal formula-
tions was calculated (Table 4, Fig. 5). Both TSL 60 and 40 showed
signiﬁcantly lower activation energy for CF release, while the other for-
mulations exhibited higher activation energy, especially in liposomes
formulated by pure DPPC or DSPC lipids, suggesting that the obstruction
for CF release was minimal when these binary component liposomes
have a DPPC content between 40% and 60%.
3.6. The inﬂuences of PEG incorporation and PEG content on CF-TSL release
Previously we demonstrated that incorporation of more PEG-DSPE
causes a higher CF leakage at phase transition [19]. We observed that
5 mol% PEG lipid in a standard formulation with DPPC-DSPC is enough
to generate content release from TSLs. In order to investigate the effect
of pure DPPC-DSPC TSLs composition on CF release we formulated lipo-
someswith aminimal amount of PEG. To avoid aggregation of the nano-
particles 0.5 mol% PEG-DSPE is needed, which was added to all
formulations. An obvious decreased of CF release was observed from
all TSLs after reducing PEG lipid to 0.5 mol% compared to the original
formulations containing 5 mol% PEG (Fig. 6). A comparable trend was
observed concerning CF release at Tm which gradually increased from
TSL100 (7 ± 3% vs 42 ± 6% at high PEG formulation; nonparametric
Mann-Whitney test p = 0.029) to TSL20 (46 ± 6% vs 73 ± 4%; p =
0.016) when minimal PEG was applied. Interestingly, unlike other TSL
formulations CF release from TSL0 seemed not to be inﬂuenced by
PEG content, showing 40 ± 4% and 49 ± 10% (p = 0.114) release at
high and low PEG formulations, respectively.
3.7. The inﬂuences of cholesterol amount on CF-TSL release
Cholesterol is commonly used in many liposomal formulations,
whichmay however affect release kinetics proﬁle of thermosensitive li-
posomes. Based on the Doxil-like formulation, we investigated CF re-
lease from TSLs composed of DSPC and 40, 20 and 10 mol%
cholesterol. DSCmeasurements (Fig. 7A) of these TSLs displayed a grad-
ually widened and slightly declined phase transition temperature whenFig. 5. Activation energy of CF release from liposomes composed of various amount of
DPPC-DSPC. *Kruskal-Wallis test followed by Dunn test, p value b 0.05; ns, not
signiﬁcant at the 0.05 probability level.increasing cholesterol from 10 mol% to 20 mol% in comparison with no
cholesterol contained TSL.However, no phase transition can bedetected
when 40 mol% cholesterol was applied. Temperature-dependent re-
lease assays conﬁrmed these observations with absent CF release at
40 mol% cholesterol, while approximate 20% CF release was observed
in formulations containing 10 and 20 mol% cholesterol formulations,
both of which showed dramatic release decrease compared to the orig-
inal formulation.
4. Discussion
Here we demonstrate that bi-component DPPC-DSPC based TSLs
have an optimal lipid ratio at which release rate at transition tempera-
ture is maximal. We observe that with the increase of the amount of
DSPC, release rates increase as well (rTm in Table 5), and at an appropri-
ate DPPC and DSPC ratio bi-component TSLs release signiﬁcantly faster
than mono-component liposomes at transition temperatures.
It is generally believed that thermosensitive liposomes exhibit the
highest permeability when reaching their Tm, which causes maximum
interfaces between solid and liquid phases in membranes, therefore
leading to massive release of content [10]. Besides, temperature may
be positively correlated to release rate [24] as the maximum release
rates of these 6 formulations were measured at different and also in-
creasingly higher transition temperatures. In order to elucidate DPPC-
DSPC based TSL release kinetics, based on the general rules of diffusion
release, namely Fick's ﬁrst law, CF release rate can be given by:
r ¼−D  A  dC=dx ¼−K  T  A  dC=dx
where D represents the diffusion coefﬁcient and is proportional to
temperature, which can be presented as the product of temperature T
and constant K in this case. A is the diffusion area of release, and dC/
dx is CF concentration gradient inside and outside of the liposomal
membrane, which is the same in all TSL formulations. Herein both tem-
perature and the release area in membrane affect CF release rates. The
interfaces between solid and liquid phases inmembrane of each formu-
lation, namely release areas, reach maximum at their respective Tm.
When we compare the TSL release rates using the experimental data
measured at the same temperature most of these TSL are not in the
maximum solid-liquid interface density. In order to compare their max-
imum release rates and eliminate the temperature factor we used the
deﬁnite integral form of the Arrhenius equation (see below) to calculate
the theoretical release rates. To do so we chose a given and same tem-
perature for all TSL formulations but maintained the maximum release
areas for each TSL formulation. Thus their solid-liquid interfaces are
remained as maximum as are at their respective Tm, but the tempera-
ture is uniﬁed at in this case at 42 °C to calculate the theoretical release
rates of each formulation (Table 5).
In kTm=k42ð Þ ¼ In rTm=r42ð Þ ¼ Ea  Tmax−T42ð Þ= R  Tmax  T42ð Þ
where rTm is the CF release rate measured at Tm of each TSL formu-
lation, which was obtained from the results in Section 3.3. Ea is the ac-
tivation energy of CF release, R is the universal gas constant, and T is
expressed as thermodynamic temperature in kelvin.
Release rates (r42) in Table 5 show the same trendof faster CF release
rates with increasing amount of DSPC in liposomes from TSL 100 to 20
but with a drop in TSL 0, implying that temperature is not the main
Fig. 6. Effect of PEG amount (5 mol% (open symbol) and 0.5 mol% (closed symbol)) on temperature-dependent CF release from DPPC-DSPC based liposomes in FCS. Mean ± SEM are
shown of 3 or more independent experiments. *Nonparametric Mann-Whitney test, p value b 0.05; ns, not signiﬁcant at the 0.05 probability level.
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We postulate that other factors intrinsic to the TSL formulation and
used components determine release kinetics.
As seen in Fick diffusion equation, the increase of DSPC in TSL may
increase the release area, thus leading to higher release. Hence, we hy-
pothesize that the amount of interfaces in the liposomal membrane
varies as a consequence of DPPC/DSPC ratios. The underlying mecha-
nism we propose is that optimizing the amount of DSPC generates
more solid-liquid interfaces in the membrane, increasing the release
areas, thus improving CF release rate at phase transition.
Binary phase diagrams can be used to illustrate the explanation of
increased release areas inDPPC-DSPC based TSLs (Figs. 2 and 4B). Unlike
theoretical prediction, the experimental phase diagram did not exhibit
“closed” curves in TSL 100 and 0 liposomes, which is because this is
not pure bi-component system in literally. The presence of PEG lipid
and interaction with serum factors as well can inﬂuence phase transi-
tion temperature of TSL 100 and 0, resulting in the deviation from the
theory [25]. Fig. 2, was drawn on the basis of data measured by DSC,
which reﬂects the macro thermodynamic behavior of lipid membrane
at milligram scale. While Fig. 4B was plotted based on the amount of
CFmolecules released through the lipidmembrane during phase transi-
tion, reﬂecting the detection of mesoscopic behavior at nanogram scale.
Apparently, the latter is more sensitive as well as closer to reality whenFig. 7. DSC scans (A) and temperature-dependent release (B) of liposomes composed of 40, 2
Mean ± SEM.tracking lipid membrane phase transition, which is able to indicate the
phase changes in lipid membrane earlier. Therefore, it is reasonable
and reliable to illustrate liposomal thermostability on the basis of the
extent of content release.
According to Fig. 4B, the molar ratios of gel and liquid phase in lipo-
somal membranes at respective transition temperatures can be calcu-
lated by Lever Rule (Fig. 8 and Table 6).
Lever Rule : ns quantity of solidsð Þ  Ls distance to solidus or to Y axisð Þ
¼ nl quantity of liquidð Þ  Ll distance to liquidus or to Y axisð Þ
It was found that in TSL 60, 40 and 20 at Tm, which showedmassive
release, the lipid membranes were composed of nearly equal amount of
gel phase and liquid crystalline phase, which may generate the maxi-
mum solid/liquid interfaces in the membranes for content release.
However, around two third of the lipid membranewas in liquid crystal-
line state in TSL 80 at Tm, thus inducing less interfaces between solid
and liquid phases, and hence diminishing CF release.
Binary-component systems are inhomogeneous during crystal nu-
clei formation and growth. Based on the above depicted DPPC-DSPC
pseudo-binary phase diagram (Fig. 8), the composition of crystal grains
is constantly changingwhen cooling down from liquid crystalline phase0, 10 and 0 mol% cholesterol and DSPC. Results of 3 independent experiments are shown
Table 5
CF release from different DPPC-DSPC based liposomes.
TSL 100 TSL 80 TSL 60 TSL 40 TSL 20 TSL 0
rTm (%/min) 9.9 ± 1.3 20.4 ± 3.2 38.6 ± 14.4 51.3 ± 16.9 65.3 ± 6.9 45.1 ± 12.2
Tmax (°C) 40 42 44 47 50 53
Ea (J/mol) 14,029 11,447 10,118 9866 14,621 18,503
r42 (%/min) 10.3 ± 1.3 20.4 ± 3.2 37.7 ± 14.1 48.4 ± 16.1 56.9 ± 6.0 35.5 ± 9.6
rTm (%/min): the experimentally measured CF release percentage in 1 min at maximum release temperature.
Tmax: temperature of maximum CF release.
Ea: CF release activation energy in average.
r42 (%/min): the theoretically calculated CF release percentage for 1 min at 42 °C based on Arrhenius equation.
Mean ± SD, N ≥ 3.
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little DPPC during cooling, and DPPC increasingly accumulates at the
growing grains due to its lower melt point. Meanwhile solidiﬁed DSPC
gradually decreases with temperature decline. For example TSL 60 in
Fig. 8, when temperature declines to point E (48 °C), numerous crystal
nuclei are formed as solid solution which is composed of 4.3% DPPC
and 95.7% DSPC. Growing crystal grains are subsequently formed by
continuous accumulation of solidiﬁed lipids to the crystal nuclei with
further cooling down, of which the percentage of DPPC is gradually in-
creased with the line F (48 °C, 4.3% DPPC) to G (39 °C, 60% DPPC).
These crystal grains stop growing when touching their adjacent grains.
Therefore, the content of DSPC in a crystal grain is decreases from crystal
nucleus to outward region, while the content of DPPC keeps increasing.
Inhomogeneous, multilayer structured crystal grains are largely formed
in bi-component membranes in this way, with gradually loweredmelt-
ing points from the core to the outer layers of each crystal grain.
Hence, according to analysis of the binary phase diagramwepropose
that a DPPC-DSPC based bi-components liposomal membrane is com-
posed of a large amount of these inhomogeneous, nano-sized crystal
grains (Fig. 9). The contact regions of these crystal grains, namely the
outmost layers of crystal grains, form the crystal grain boundaries
(green stripe in Fig. 9) and, are rich in DPPC, thus leading to a lower
melting point in these regions compared with inner layers of crystal
grains which are rich in DSPC. Consequently, a priori phase transition
occurs at these boundary regions at transition temperature when
heating up, which generates these crystal grains outmost layers to
melt but inner layers stay solid, thus forming solid-liquid interfaces
which allow content release in bi-component TSLs. However, in
mono-component liposomes homogeneous crystal grains are formedFig. 8. Pseudo-binary phase diagram modiﬁed from Fig. 4B. A, B, C and D represent the
maximum release temperatures of respective CF-TSLs and their distances to solidus and
liquidus (along the drawn solid red line) were used to calculate solid/liquid phase ratios
at Tm. For TSL 20, Ls is distance from D to left Y axis; from A to right Y axis is Ll for TSL
80. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)in membranes, with a homogeneous melting point from nucleus to
outer region (Fig. 9). Thus, no solid-liquid interfaces are formed be-
tween crystal grains of mono-component membrane at transition
temperature.
Next to the crystal grain formation, membrane defects (black stripes
in Fig. 9) are formed between membrane domains due to the curved
spherical liposome surface [12]. Highly disordered arrangement of
lipid molecules occurs because of different lattice orientation [11],
resulting in a lower melting point in these defect regions. Hence priori
phase transition takes place in these regions in both bi- andmono-com-
ponent TSLs at transition temperature, forming interfaces between solid
and liquid phases for content release (Fig. 9).We argue that melting not
only happens at defect regions but also at numerous crystal grain
boundaries during phase transition. Thus bi-component membranes
generate signiﬁcantly increased solid-liquid interfaces thanmono-com-
ponentmembranes, which onlymelt at defect regions at Tm(Fig. 9mid-
dle row), this results in faster and more content release in bi-
component TSLs. When heating above Tm, the whole liposome mem-
brane is in a liquid phase which takes away the solid-liquid interfaces,
thus evidently decreasing release as we observed in both bi- and
mono-component TSLs (Fig. 9 top row).
In bi-component liposomes, however, maximum release varies sig-
niﬁcantly between TSL 60, 40 and 20. Table 5 shows almost the same
solid-liquid phase ratios between these TSL 60, 40 and 20 at their max-
imum release temperatures, but that does not imply that the amount of
interfaces between gel and liquid crystalline phases are the same. One
possible explanation could be that more crystal grains are formed
when liposomal membranes containing more DSPC, which hence gen-
eratesmore solid-liquid boundaries at transition temperatures. Another
possibility is that due to the longer chain length and higher rigidity of
DSPC compared to DPPCmolecules, moremembrane defects are gener-
ated in liposomal membranes containing more DSPC as a consequence
of higher curvature stress (Fig. 9 TSL 0). We indeed observed that
when the size is increased (Supplementary Fig. 1, Supplementary
Table 1), lack of curvature stress in the lipid membrane caused dramat-
ically reduced release, especially in mono-component TSLs which
showed comparable extend of CF leakage (Supplementary Fig. 1 TSL
100 vs TSL 0); while bi-component TSL still demonstrated, but reduced,
heat-triggered release (Supplementary Fig. 1 TSL 60).
According to the phase diagram in Fig. 8, the gel phase occupies 60%
of themembrane in TSL 20when cooling down to point H (calculated by
Lever Rule). In addition,more than half of themembrane in TSL 20 is so-
lidiﬁed and formed by pure DSPC lipids at point H, thus creating a pure
DSPC-based continuous phase in membrane. While during cooling of
TSL 40 and 60, the continuous phases are solid solution composed of
DSPC and DPPC rather than pure DSPC. Continuous phases formed by
pure DSPC structurally differ from those formed by DPPC/DSPC solid so-
lution. This may be another reasonwhy TSL 20 and 0, with pure DSPC as
continuous phase inmembranes, showed higher release than TSL 60, 40
and 100.
The activation energy of CF release (Fig. 5) gradually decreased from
TSL 100 to 40, which is due to the increased number of interfaces in
membranes that facilitate CF release. It requires high activation energy
Table 6
The ratios of solid and liquid phase in liposomal membranes at maximum CF release tem-
perature of different DPPC-DSPC based liposomes.
TSL 100 TSL 80 TSL 60 TSL 40 TSL 20 TSL 0
Tmax (°C) 40 42 44 47 50 53
n(s):n(l) (mol/mol) – 0.44 1.00 0.94 1.00 –
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hydrophobicity and thickness of the membrane as a consequence of
continuous phases composed of pure DSPC lipid in TSL 20 and 0, thus
needinghigh activation energy for CF release. However, it seems that re-
lease from areas with enhanced leakiness, as results of bending defects
in membranes, supersedes the release obstruction resulting from high
activation energy. Therefore TSL 20 and 0 still showed fast CF release.
Komatsu et al. demonstrated that content release from a liposomal
aqueous core followsﬁrst order kinetics [27]. However, based on thede-
termination coefﬁcient R2 (Table 3) resulted from ﬁtting by three kinet-
ic equations in Section 2.5, we found that CF release better correlates
with the Higuchi model when liposome contained DPPC more than or
equal to 40%. While it is proper described by the ﬁrst-order release
model when more than 80% of the liposomal membrane is made up
by DSPC. The Higuchi model describes pore-based release models [28],
which suggests that especially TSL 80–40 are likely to present a pore-
like release proﬁle during phase transition. These nano-scale pores re-
sult from the large amount of solid-liquid interfaces in bi-componentFig. 9. Crystal grains in bi-component liposomal membranes are formed as inhomogeneous mi
grains in a homogenous (i.e. mono-component) structure have the same melting point acro
temperatures, both grain boundary (green stripe) and defect (black stripe) regions melt
component TSLs at transition temperatures, thus creating less gel/liquid interfaces for content
phase, thus no interfaces for release are present. The transmission electron microscopy gra
publisher. (For interpretation of the references to color in this ﬁgure legend, the reader is refermembranes. While for TSL 20 and 0, due to the increase of long chain
DSPC lipids in TSL the membranes become thicker, leading to increased
diffusion path length for CF inmembrane, thus displaying ﬁrst-order re-
lease pattern [28]. Importantly, in this study the ﬁtting differences of
these TSL release proﬁles are not signiﬁcant.
Taken together we conclude that interfaces between gel and liquid
crystalline phases are crucial formassive release of content at Tm.More-
over, while typically liposomes are coated with PEG to prolong circula-
tion time, PEG facilitates rapid release kinetics aswell. PEG lipids tend to
accumulate at interface areas due to their surface activity, consequently
stabilizing these interfaces to release CF [9]. Therefore, when liposomes
contain a low content of PEG lipids dramatically diminished CF release
was observed (Fig. 6). The lack of such an effect in TSL 0may be because
the resulting interfaces in TSL 0 aremore rigid due to pure DSPC compo-
sition, therebymore stable interfaces are generated in TSL 0membranes
enabling CF release even without help of PEG. Additionally, PEG lipid
(DSPE-PEG) has the same lipid moiety as DSPC rather than DPPC,
which could also explain the signiﬁcant decreased release in TSL 100
containing lower PEG lipids. Cholesterol is applied to improve the stabil-
ity of liposomalmembranes, but it alsomaintains a certain degree of ﬂu-
idity of the membrane above as well as below Tm [29]. Through this
action cholesterol passivates the response of TSL membrane to transi-
tion temperature by inserting between lipid molecules which affects
inter-molecular ordered arrangement of phospholipids in the mem-
brane [23,29]. As a result, we think, cholesterol molecules obscure
membrane defects and boundaries, leading to less or no interfacescrostructures with lower melting point in the outer layer, while mono-component crystal
ss the grains. In membrane defect regions the melting point is also lower. At transition
(pink) in bi-component TSLs, whereas only membrane defect regions melt in mono-
release in TSL 100 and 0. When above transition temperatures, all TSLs are in pure liquid
ph of lipid membrane is cited from paper of Landon et al. [26] and authorized by the
red to the web version of this article.)
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creases themembrane lipophilicity and therefore barrier function to hy-
drophilic compounds which likely explains the remarkable decrease of
CF release and declined thermosensitivity as observed in cholesterol
containing liposomes (Fig. 7).
Considering the applicable hyperthermia range in the clinic (40–
43 °C), a DPPC content has to be selected which balances instability
with rapid release. TSLs with a DPPC content above 80% are prone to
leak at around physiological temperature because the membrane al-
ready goes through phase transition at 37 °C (Fig. 8). The onset of
phase transition of liposomes with a DPPC content of 40% or lower on
the other hand, starts at 41 °C, with only a minor fraction of the lipids
convert to a liquid state. Based on Level Rule, the percentage of liquid
crystalline phase in the membrane at this state is still low (~17%)
even at 43 °C, thus generating lesser interfaces for release. Therefore,
in DPPC-DSPC based thermosensitive liposomes the amount of DPPC
should be above 40% and not beyond 80% for a fast triggered drug re-
lease at a preferred hyperthermia temperature.
5. Conclusion
Thermosensitive liposomes are promising delivery systems for solid
tumor treatment combined with local hyperthermia. It is crucial that
TSLs display rapid content release when exposed to the right tempera-
ture, generating a steep drug gradient which beneﬁts subsequent
tumor uptake. The presentwork, based on the analysis of phase equilib-
rium, illustrates that inhomogeneous crystal grains consisting mem-
branes form in DPPC-DSPC bi-component TSLs. These inhomogeneous
microstructurally organized membranes offer numerous solid-liquid
phase interfaces, namely nano-scale gaps, at transition temperature at
crystal grain boundaries and defect regions, enabling rapid release.
These induced nano-scale gaps in liposome membranes are adjustable
in quantity by changing DPPC and DSPC ratios, thus presenting different
release kinetics, which can be used to further develop TSLs forwider ap-
plication in the clinic.
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